Overview

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, randomized controlled, Phase 3 clinical trial.
Phase:
PHASE3
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.
Treatments:
Everolimus
exemestane
Fulvestrant